Hence, deleting Ebag9 in engineered T cells might be suitable for therapeutic exploitation, foremost in adoptive T cell transfer targeted at hematopoietic neoplasm. The gene discussed is EBAG9; the disease is hematopoietic and lymphoid cell neoplasm.